Trial Profile
Dose escalation study to assess the safety and tolerability of incremental doses of QAB149 [indacaterol] in adults with mild-to-moderate chronic obstructive pulmonary disease (COPD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2011
Price :
$35
*
At a glance
- Drugs Indacaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Novartis
- 24 Dec 2005 New trial record.